Bizarre Patents
Hands free towel carrying system
A hands free towel carrying system for coupling a towel to a user to prevent loss, theft or contamination.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8182814 | Methods of treating inflammatory airway conditions by inhibition of IL-11 activity The present invention provides a method for the treatment or prophylaxis of T-helper type 2 (Th2)-mediated disorders using antagonists of IL-11. ... | 05/22/2012 |
| 8183225 | Inhibition of bone resorption using medical implants containing adenosine receptor antagonists The invention provides methods and compositions for reducing or inhibiting bone resorption, osteoclast differentiation and stimulation and the loosening of medical prostheses by administering a compound or agent that modulates an adenosine receptor such as the adeno... | 05/22/2012 |
| 8178107 | Method of treatment of thrombocytopenia or risk thereof using MPL ligand (thrombopoietin), variants, and fragments thereof Isolated mpl ligand, isolated DNA encoding mpl ligand, and recombinant or synthetic methods of preparing mpl ligand are disclosed. These mpl ligands are shown to influence the replication, differentiation or maturation of blood cells, especially megakaryocytes and m... | 05/15/2012 |
| 8178101 | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the s... | 05/15/2012 |
| 8147844 | ligand (thrombopoietin), nucleic acids encoding such, and methods of treatment using ligand Isolated thrombopoietin (TPO), isolated DNA encoding TPO, and recombinant or synthetic methods of preparing and purifying TPO are disclosed. Various forms of TPO are shown to influence the replication, differentiation or maturation of blood cells, especially megakar... | 04/03/2012 |
| 8138141 | HMG1 antibody for treating inflammatory conditions There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method f... | 03/20/2012 |
| 8133724 | Human androgen receptor alternative splice variants as biomarkers and therapeutic targets The present invention relates to novel androgen receptor splice variants (AR3, AR4, AR4b, AR5 and AR8) and variants and fragments thereof which have a role in the progression of androgen independent prostate cancer. The invention further relates to compositions and ... | 03/13/2012 |
| 8133490 | Method and system to remove cytokine inhibitors in patients A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the... | 03/13/2012 |
| 8129124 | Agents and methods related to reducing resistance to apoptosis-inducing death receptor agonists Provided herein is a method of reversing or preventing a target cell's resistance to a death receptor agonist. Also provided are methods of screening for biomarkers resistance of and monitoring resistance to death receptor agonists. Also provided are methods of sele... | 03/06/2012 |
| 8124352 | Methods and compositions for targeting HEPSIN Anti-HEPSIN monoclonal antibodies, and methods for using the antibodies, are provided. ... | 02/28/2012 |
| 8124084 | Compositions and methods for immunomodulation in an organism using IL-15 and soluble IL-15Ra The present invention relates to a therapeutic polypeptide and methods for its creation and use for modulating an immune response in a host organism in need thereof. In particular, the invention relates to the administration to an organism in need thereof, of an eff... | 02/28/2012 |
| 8105842 | Interleukin-13 as a cardiovascular disease marker The present invention relates to use of interleukin-13 as a cardiovascular disease marker. The therapeutic composition and diagnostic composition of the invention for cardiovascular diseases are characterized by comprising an antibody to an interleukin-13 receptor a... | 01/31/2012 |
| 8101188 | Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections Described is the modulation of the neovascularization and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and/or the growth of collateral arteries and/or other arte... | 01/24/2012 |
| 8101158 | Methods for treating cerebrovascular disease comprising administering an agent that inhibits prokineticin receptor activity The present invention relates to a method of identifying agents that modulate prokineticin receptors, particularly, in the brain. Such agents are useful in the treatment of cerebrovascular diseases, including cerebral ischemia, cerebral hemorrhage, ischemic stroke, ... | 01/24/2012 |
| 8097584 | Stabilized formulations of insulin that comprise ethylenediamine The present invention relates to a pharmaceutical formulation comprising insulin, an insulin analogue or an insulin derivate and ethylenediamine or salts thereof and an antimicrobial preservative agent. ... | 01/17/2012 |
| 8088889 | Teneurin c-terminal associated peptides (TCAP) and uses thereof The invention provides a novel family of biologically active neuropeptides and the nucleic aid molecules coding for same. The peptides are derived for the C-terminus of the teneurin family peptides (Ten M1-4). These novel peptides, referred to as teneurin C-terminal... | 01/03/2012 |
| 8088381 | Methods of treatment of cardiovascular disease using anti-CTGF agents The present invention relates to methods for treating impaired cardiac function. Methods for treating various physiological and pathological features associated with cardiac dysfunction by administering an agent that inhibits the expression or activity of connective... | 01/03/2012 |
| 8088600 | Nucleic acids encoding cynomolgus IL-13 mutein proteins The present invention relates to at least one novel cynomolgus IL-13 muteins (Mut-IL-13) proteins, antibodies, including isolated nucleic acids that encode at least one Mut-IL-13 protein or antibody, Mut-IL-13 vectors, host cells, transgenic animals or plants, and m... | 01/03/2012 |
| 8084225 | Methods for diagnosing cerebrovascular events based on NR2 peptides Methods and kits for diagnosing and treating cerebrovascular events, and for defining the time and anatomical location of an event, are provided based on the detection and quantification of bound or total and unbound NR2 peptides in biological fluids. The methods ar... | 12/27/2011 |
| 8075891 | Antibodies that bind ALS specific epitopes and methods of making The invention relates to an epitope protection assay for use in diagnosis, prognosis and therapeutic intervention in diseases, for example, involving polypeptide aggregation, such as prion infections. The methods of the invention first block accessible polypeptide t... | 12/13/2011 |
| 8071375 | Use of IL-6-type cytokines for maturation of oocytes The use of certain IL-6-type cytokines for the in vitro maturation of mammalian oocytes is described. The in vitro matured oocytes may be used in in vitro fertilization protocols. ... | 12/06/2011 |
| 8066993 | Use of ventricular enlargement rate in intravenous immunoglobulin treatment of Alzheimer's disease The present invention relates to the use of MRI monitoring of ventricular enlargement rate as an objective measure for the purpose of assessing disease progression in patients suffering from Alzheimer's disease and for the purpose of determining therapeutic effectiv... | 11/29/2011 |
| 8067001 | Antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof An antibody of the invention interacts with human DR5 to produce agonistic or antagonistic effects downstream of the receptor including inhibition of cell proliferation and apoptosis. Nucleic acid sequences and amino acid sequences of anti-DR5 antibodies have been e... | 11/29/2011 |
| 8066997 | Modulation of activity of neurotrophins The present invention relates to methods for modulating the activity of one or more neurotrophins, such as neural growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3, and neurotrophin-4 (NT-4), in an animal and methods for treatment of a di... | 11/29/2011 |
| 8062864 | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the s... | 11/22/2011 |
| 8058243 | Method for treating a brain cancer with ifenprodil A clonogenic neurosphere assay is described that carries out high throughput screens (HTS) to identify potent and/or selective modulators of proliferation, differentiation and/or renewal of neural precursor cells, neural progenitor cells and/or self-renewing and mul... | 11/15/2011 |
| 8053206 | Antagonists of HMG1 for treating inflammatory conditions There is disclosed a pharmaceutical composition and method for treating sepsis, including septic shock and ARDS (acute respiratory distress syndrome), comprising administering an effective amount of a HMG1 antagonist. There is further disclosed a diagnostic method f... | 11/08/2011 |
| 8052976 | Growth factor homolog ZVEGF3 Polypeptide growth factors, methods of making them, polynucleotides encoding them, antibodies to them, and methods of using them are disclosed. The polypeptides comprise an amino acid segment that is at least 90% identical to residues 46-163 of SEQ ID NO:2 or residu... | 11/08/2011 |
| 8044187 | Human luteinizing hormone superagonists The invention is directed toward a human glycoprotein hormone having at least one, two, three, four, or five basic amino acids in the α-subunit at positions selected from the group consisting of positions 11, 13, 14, 16, 17, and 20. The invention is also directed t... | 10/25/2011 |
| 8039437 | Fn14/TRAIL fusion proteins Fusion proteins which act on the TWEAK and TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, as well as other diseases such as alloimmune diseases and cancer. ... | 10/18/2011 |
| 8034786 | Methods and means for controlling the endocytosis and subsequent degradation of growth hormone receptor The invention relates to the field of regulating metabolic processes, for example, to regulate the presence and/or activity of a receptor at the surface of a cell. The invention provides a method for controlling the presence of a receptor at the surface of a cell co... | 10/11/2011 |
| 8026072 | Method of identifying compounds that bind BAFF-R Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and... | 09/27/2011 |
| 8017112 | Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS). ... | 09/13/2011 |
| 8017748 | Antibody neutralizers of human granulocyte macrophage colony stimulating factor The present invention relates to a human monoclonal antibody or fragment thereof which specifically binds to and neutralizes primate GM-CSF. ... | 09/13/2011 |
| 8008261 | Methods of reducing trail-induced apoptosis by trail isoforms This document provides to methods and materials related to apoptosis. For example, methods and materials for modulating apoptosis are provided. In addition, methods and materials for treating a mammal having an apoptosis-associated condition are provided. ... | 08/30/2011 |
| 8008025 | Biomarkers for neurodegenerative disorders The present invention provides methods for diagnosing neurodegenerative disease, such as Alzheimer's Disease, Parkinson's Disease, and dementia with Lewy body disease by detecting a pattern of gene product expression in a cerebrospinal fluid sample and comparing the... | 08/30/2011 |
| 7994136 | Metalloproteinase inhibitor A novel metalloproteinase inhibitor, analogs thereof, polynucleotides encoding the same, and methods of production, are disclosed. Pharmaceutical compositions and methods of treating disorders caused by excessive amounts of metalloproteinase are also disclosed. ... | 08/09/2011 |
| 7993659 | TLR9 agonist and CD40 agonist immunostimulatory combinations The present invention provides immunostimulatory combinations. Generally, the immunostimulatory combinations include a TLR agonist and a TNF/R agonist. Certain immunostimulatory combinations also may include an antigen. ... | 08/09/2011 |
| 7989584 | AKT nucleic acids, polypeptides, and uses thereof The present invention relates to human Akt3 proteins and polypeptides. The invention also relates to isolated nucleic acids encoding human Akt3, to vectors containing them and to their therapeutic uses, in particular for gene therapy. Expression of Akt3 inhibits cel... | 08/02/2011 |
| 7988964 | NOGO-a neutralising immunoglobulin for treatment of neurological diseases The present invention provides immunoglobulins, particularly antibodies that bind to NOGO and neutralise the activity thereof, polynucleotides encoding such antibodies, pharmaceutical formulations containing said antibodies and to the use of such antibodies in the t... | 08/02/2011 |
